Chronic Progressive Fibrosing Interstitial Lung Disease

Drug	Drug Name	Drug Description
DB09079	Nintedanib	A triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer.

Drug	Drug Name	Target	Type
DB09079	Nintedanib	Vascular endothelial growth factor receptor 1	target
DB09079	Nintedanib	Vascular endothelial growth factor receptor 2	target
DB09079	Nintedanib	Vascular endothelial growth factor receptor 3	target
DB09079	Nintedanib	Platelet-derived growth factor receptor alpha	target
DB09079	Nintedanib	Platelet-derived growth factor receptor beta	target
DB09079	Nintedanib	Fibroblast growth factor receptor 1	target
DB09079	Nintedanib	Fibroblast growth factor receptor 2	target
DB09079	Nintedanib	Fibroblast growth factor receptor 3	target
DB09079	Nintedanib	Receptor-type tyrosine-protein kinase FLT3	target
DB09079	Nintedanib	Tyrosine-protein kinase Lck	target
DB09079	Nintedanib	Tyrosine-protein kinase Lyn	target
DB09079	Nintedanib	Proto-oncogene tyrosine-protein kinase Src	target
DB09079	Nintedanib	P-glycoprotein 1	transporter
DB09079	Nintedanib	Cytochrome P450 3A4	enzyme
DB09079	Nintedanib	Solute carrier family 22 member 1	transporter
DB09079	Nintedanib	Serum albumin	carrier
DB09079	Nintedanib	UDP-glucuronosyltransferase 1-1	enzyme
DB09079	Nintedanib	UDP-glucuronosyltransferase 1-7	enzyme
DB09079	Nintedanib	UDP-glucuronosyltransferase 1-8	enzyme
DB09079	Nintedanib	UDP-glucuronosyltransferase 1-10	enzyme
DB09079	Nintedanib	ATP-binding cassette sub-family G member 2	transporter

Drug	Drug Name	Phase	Status	Count